Multiple sclerosis (MS) is a neurodegenerative disorder and an autoimmune disease. Until now, observational studies have indicated the association of bone mineral density (BMD) and fracture with the risk of MS. However, these studies indicated inconsistent findings. Until now, genome-wide association studies (GWAS) have been conducted in BMD, fracture, and MS, which provide large-scale datasets to investigate the causal association of BMD and fracture with the risk of MS using the Mendelian randomization (MR) study. Here, we performed an MR study to clarify the causal association between BMD/fracture and the risk of MS using large-scale publicly available GWAS datasets from BMD, fracture, and MS. We first evaluated the bidirectional causal effects of BMD and MS. The main analysis method inverse-variance weighted (IVW) showed no significant causal effect of BMD on the risk of MS (β = 0.058, and p = 1.98E-01), and MS on the risk of BMD (β = −0.001, and p = 7.83E-01). We then evaluated the bidirectional causal effects of fracture and MS. However, we only identified a significant causal effect of fracture on the risk of MS using IVW (β = −0.375, p = 0.002), but no significant causal effect of MS on the risk of the fracture using IVW (β = 0.011, p = 2.39E-01). Therefore, our main analysis method IVW only found a significant causal effect of fracture on MS using the threshold for the statistically significant association p < 0.05/4 = 0.0125. Meanwhile, multivariable MR analyses showed that the causal effect of fracture on MS was independent of smoking, drinking, and obesity, but dependent on BMD. In summary, our MR analysis demonstrates that genetically increased fracture may reduce the risk of MS. Our findings should be further verified and the underlying mechanisms should be further evaluated by future studies.
Study Design. An experimental animal study with randomized, control design was conducted using a dog model. Objective. To construct a novel posterior lumbar spine fusion model with orthotopic paraspinal muscle-pediculated bone flaps and to compare with the conventional posterolateral lumbar intertransverse process fusion. Summary of Background Data. Previous studies have demonstrated that paraspinal musculature provided important vascular ingrowth into the fusion mass. However, the blood supply of paraspinal muscles was still not sufficiently used in spinal fusion. In this study, we assessed the significant role of orthotopic paraspinal muscle-pediculated bone flaps in the healing of bone graft in spinal fusion. Methods. Thirty-two mongrel dogs were randomly assigned to 2 groups to undergo either posterior spinal fusion with orthotopic paraspinal muscle-pediculated bone flaps (treatment group) or posterolateral intertransverse process fusion (control group) at L5–L6 segment. All the fusions used an autologous bone graft obtained from bilateral posterior iliac crests. The animals were killed at 8 weeks or 16 weeks after surgery. The lumbar spines were evaluated by radiology, histology, and biomechanics. Results. Treatment groups showed an increasing trend on radiographic grades, manual palpation, and biomechanical stiffness compared with control groups at 8 and 16 weeks. Histologic analysis revealed that there was more mature woven bone in the treatment group than the controls at both points. At 8 weeks, the histologic fusion rate was 21.4% in the treatment group, 50% in the control group (P < 0.05); and at 16 weeks the fusion rate was 50% and 87.5% in the control group and the treatment group, respectively (P < 0.05). Conclusion. The use of orthotopic paraspinal musclepediculated bone flaps increased the rate and quality of fusion in the experimental spinal fusion model. This suggested that the novel posterior spinal fusion could be further developed for clinical application.
12 January 2026 in Journal of Materials Chemistry B
The repair of severe bone defects remains a major clinical challenge. While our team has developed a Si-CaP material with significant potential for bone defect repair, its limitations in application convenience and poor degradability have hindered practical use. This study addresses these issues by creating an injectable light-curable P24–Si-CaP/GelMA (P-Si/G) composite hydrogel, further enhancing Si-CaP's osteogenic capacity through P24 peptide grafting. The composite material integrates P24–Si-CaP bio-ceramic powder (with surface-modified osteogenic peptide) into a GelMA hydrogel matrix. Experimental results demonstrate that when the Si-CaP/GelMA mass ratio is 20%, the hydrogel exhibits optimal gel-forming capability, mimics the inorganic/organic ratio of natural bone, and maintains excellent mechanical strength. Comprehensive characterization confirmed successful peptide conjugation, resulting in superior porosity and enhanced hydrophilicity. In vitro experiments showed that P-Si/G hydrogel significantly promotes the migration and osteogenic differentiation of rat bone marrow mesenchymal stem cells (rBMSCs), evidenced by increased alkaline phosphatase activity, mineralization, and enhanced expression of osteogenic genes, with no observed cytotoxicity. In a rat cranial defect model, micro-CT and histological analysis revealed that the P-Si/G hydrogel group achieved significantly higher new bone formation and near-complete defect closure after 8 weeks of implantation compared to control, pure GelMA, and Si-CaP/GelMA groups, demonstrating in vivo safety. Comprehensive research demonstrates that the P24–Si-CaP/GelMA composite hydrogel exhibits outstanding biocompatibility, osteogenic induction, and bone-conducting properties, making it a highly promising injectable scaffold material for bone tissue engineering.
1 August 2023 in Journal of Cancer Research and Clinical Oncology
Purpose: Cervical adenocarcinoma is one of the most common types of cervical cancer and its incidence is increasing. The biological behavior and treatment outcomes of cervical adenocarcinoma (CA) differ from those of squamous cell carcinoma (SCC). We sought to develop a model to predict recurrence and cancer-specific survival (CSS) deaths in CA patients. Methods: 131 patients were included in model development and internal validation, and patients from the SEER database (N = 1679) were used for external validation. Multivariable Cox proportional hazards regression analysis was used to select predictors of relapse-free survival (RFS) and CSS and to construct the model, which was presented as two nomograms. Internal validation of the nomograms was performed using the bootstrap resampling method. Results: Age, FIGO (International Federation of Gynecology and Obstetrics) stage, size of the tumor, lymph metastasis and depth of invasion were identified as independent prognostic factors for RFS, while age, FIGO stage, size of the tumor and number of positive LNs were identified as independent prognostic factors for CSS. The nomogram of the recurrence model predicted 2- and 5-year RFS, with optimism adjusted c-statistic of 75.41% and 74.49%. Another nomogram predicted the 2- and 5-year CSS with an optimism-adjusted c-statistic of 83.22% and 83.31% after internal validation; and 68.6% and 71.33% after external validation. Conclusions: We developed and validated two effective nomograms based on static nomograms or online calculators that can help clinicians quantify the risk of relapse and death for patients with early-stage CA.